The recently published International Society of Hypertension (ISH) 2020 guidelines recommend the preferred use of ACE inhibitors or angiotensin-receptor blockers with CCBs in the management of hypertension [3] on the basis of the results of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT) [19] and the Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial [20]. This evidence concerns the gene ACE and Hypertension.